Related Experiment Video
Updated: Oct 2, 2026
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis
Maria G Garcia1, Alan D Hutson, Robert D Christensen
1The National Institute of Perinatology, Mexico City, Mexico.
Insights
Recombinant erythropoietin (rEpo) given to very low birth weight (VLBW) infants after the first week of life significantly reduces late erythrocyte transfusions. The reduction in transfusions was dose-dependent.
Area of Science:
- Neonatal Medicine
- Hematology
- Pharmacology
Background:
- Very low birth weight (VLBW) infants often require erythrocyte transfusions due to anemia.
- Late transfusions, occurring after the first week of life, are a common complication in VLBW neonates.
- Recombinant erythropoietin (rEpo) is a therapeutic agent that stimulates red blood cell production.
Purpose of the Study:
- To determine if rEpo administration reduces late erythrocyte transfusions in VLBW infants.
- To evaluate the efficacy of rEpo in preventing transfusion needs in this vulnerable population.
- To conduct a meta-analysis of high-quality studies to assess rEpo's impact on transfusion rates.
Main Methods:
- A meta-analysis approach was employed, adhering to Cochrane Neonatal Review Group guidelines.
- A comprehensive literature search was conducted using Medline from January 1990 to November 2000.
- Inclusion criteria specified randomized, placebo-controlled, and double-masked study designs.
Main Results:
- Eight studies involving 357 VLBW neonates met the inclusion criteria (183 rEpo, 174 placebo).
- rEpo administration resulted in significantly fewer erythrocyte transfusions compared to placebo (OR=0.33, 95% CI 0.21-0.51).
- The effect of rEpo on reducing transfusions was dose-dependent (p=0.0001).
Conclusions:
- Meta-analysis of rigorous studies indicates rEpo administration effectively reduces late erythrocyte transfusions in VLBW infants.
- The beneficial effect of rEpo is observed in a dose-dependent manner.
- rEpo is a valuable therapeutic option for managing anemia and reducing transfusion requirements in VLBW neonates.
Objectives:
Using the approach of a meta-analysis, we sought to determine whether the administration of recombinant erythropoietin (rEpo) to very low birth weight (VLBW) infants, after the first week of life, results in fewer "late" transfusions.
Study Design And Methods:
The guidelines set forth by the Cochrane Neonatal Review Group were used to identify all relevant studies. Medline was searched from January 1990 to November of 2000. Studies that used a randomized, placebo-controlled, and double-masked design were deemed acceptable.
Results:
Eight studies meet the inclusion criteria. These involved 357 VLBW neonates: 183 rEpo and 174 placebo recipients. The neonates in the rEpo group received fewer erythrocyte transfusions during the study period than did those in the placebo group; the common odds ratio (OR)=0.33; 95% confidence interval (CI) 0.21-0.51. Furthermore, the rEpo effect size was a function of the dose of rEpo administered (p=0.0001).
Conclusion:
A meta-analysis of the most scientifically rigorous studies on this topic indicates that administration of rEpo to VLBW infants reduces "late" erythrocyte transfusions in a dose-dependent manner.
